Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia

Pérez-Rodríguez, Irma Margarita; García-Meléndez, Martha Elena; Eichelmann, Kristian; Vázquez‐Martínez, Osvaldo; Ocampo‐Candiani, Jorge

doi:10.1159/000357022

Cited by 6 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…-incl. Pimecrolimus Erythema, scaling [90], burning sensation and pruritus, induced lentiginosis, hyperpigmentation on the face and the hands (very rare, in association with dutasteride) [102].…”

Section: α-Reductase Inhibitors (5α-ris)mentioning

confidence: 99%

“…5α-RI Category X during pregnancy [62,107], reproductive disorders (reduction in sperm count and motility) [62], sexual disorders (decreased libido, erectile dysfunction, ejaculation disorder) [62,84,102,107,108], breast disorders (gynecomastia, mastalgia) [62,102], potential increase in breast cancer risk [107,108], psychiatric disorders (depression) [62,107,108].…”

Section: α-Reductase Inhibitors (5α-ris)mentioning

confidence: 99%

“…-incl. Finasteride Cutaneous vasculitis, drug-related folliculitis, erythema annulare centrifugum, solitary fixed drug eruption, urticarial rash and acute generalized exanthematous pustulosis [102].…”

Section: α-Reductase Inhibitors (5α-ris)mentioning

confidence: 99%

See 2 more Smart Citations

Frontal Fibrosing Alopecia – a review and a practical guide for clinicians

Kępińska¹,

Jałowska²,

Bowszyc‐Dmochowska³

2021

Ann Agric Environ Med.

View full text Add to dashboard Cite

Despite a significant increase in reported cases of frontal fibrosing alopecia (FFA) in literature, discussion about the possible role of environmental factors, instruction for diagnosis and guideline for treatment, are limited. The review aims to provide a detailed synthesis of this condition that could be used by clinicians in their practise. Whether single-centre or multicentre, studies of more than 60 cases less than 5 years old were mainly taken into consideration. Results obtained were that FFA affects mainly postmenopausal Caucasian women; the most common comorbidities are hyperlipidaemia, arterial hypertension, osteoporosis, hypothyroidism, depression, alongside dermatological disorders such as atopic dermatitis, rosacea, seborrheic dermatitis and androgenetic alopecia. Autoimmune, genetic, hormonal (e.g. estrogen deficiency, pregnancy, lactation, HRT and raloxifene) and environmental (e.g. daily use of facial sunscreens and less frequent use of hair dyes and shampoo) hypotheses were proposed for pathogenesis, as well as association with various predisposing factors (patient's health-social profile, disease's history and comorbidities). Clinical presentation of FFA can be divided into 3 specific patterns, each with a different prognosis. Diagnosis is usually made clinically with the use of trichoscopy; however, scalp biopsy remains the gold standard. The condition is regarded as a variant of lichen planopilaris (LPP) due to the similarity of the prominent histopathological findings, but the clinical image is distinct and therapeutic options vary. 5α-reductase inhibitors, intralesional steroids, and hydroxychloroquine provide the highest level of evidence for the treatment of FFA. The conclusion is that a better understanding of the disease is crucial for proper disease management.

show abstract

Section: α-Reductase Inhibitors (5α-ris)mentioning

confidence: 99%

Section: α-Reductase Inhibitors (5α-ris)mentioning

confidence: 99%

See 1 more Smart Citation

Frontal Fibrosing Alopecia – a review and a practical guide for clinicians

Kępińska¹,

Jałowska²,

Bowszyc‐Dmochowska³

2021

Ann Agric Environ Med.

View full text Add to dashboard Cite

show abstract

“…Some success has been documented with the use of peroxisome proliferator-activated receptor γ agonists like pioglitazone ( Mirmirani and Karnik, 2009 ). Finally, a combination of dutasteride and pimecrolimus was reported effective in a patient with the frontal fibrosing variant of LPP ( Perez-Rodriguez et al, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

Update on lichen planus and its clinical variants

Weston

Payette

2015

International Journal of Women's Dermatology

181

179

View full text Add to dashboard Cite

Lichen planus (LP) is an inflammatory skin condition with characteristic clinical and histopathological findings. Classic LP typically presents as pruritic, polygonal, violaceous flat-topped papules and plaques; many variants in morphology and location also exist, including oral, nail, linear, annular, atrophic, hypertrophic, inverse, eruptive, bullous, ulcerative, lichen planus pigmentosus, lichen planopilaris, vulvovaginal, actinic, lichen planus-lupus erythematosus overlap syndrome, and lichen planus pemphigoides. Clinical presentation of the rarer variant lesions may be largely dissimilar to classic LP and therefore difficult to diagnose based solely on clinical examination. However, histopathological examination of LP and LP-variant lesions reveal similar features, aiding in the proper diagnosis of the disease. Management of LP and LP variants aims to control symptoms and to decrease time from onset to resolution; it often involves topical corticosteroids, but varies depending on the severity and location of the lesion. The literature contains an array of reports on the variations in presentation and successful management of LP and its variants. A familiarity with LP and its variants is important in achieving timely recognition and management of the disease.

show abstract

“…An exception would be the description of a single case with diffuse skin hyperpigmentation after starting oral dutasteride, which remitted after the discontinuation of the therapy. 5 The main limitation of the use of 5ARIs in patients with FFA is that they are contraindicated during pregnancy and for women with childbearing potential because of teratogenicity.…”

mentioning

confidence: 99%